DalsnaFinance

Xanamem proof-of-concept trial demonstrating anti-depressant activity published in the British Journal of Psychiatry

Markets GlobeNewswire By GlobeNewswire 20 Jul 2026 12:51 1 min read
Xanamem proof-of-concept trial demonstrating anti-depressant activity published in the British Journal of Psychiatry

Ongoing Xanamem (emestedastat) Alzheimer’s disease pivotal trial progresses toward final results in November this year Ongoing Xanamem (emestedastat) Alzheimer’s disease pivotal trial progresses toward final results in November this year

Ongoing Xanamem (emestedastat) Alzheimer’s disease pivotal trial progresses toward final results in November this year Ongoing Xanamem (emestedastat) Alzheimer’s disease pivotal trial progresses toward final results in November this year

Read the full story on GlobeNewswire → Opens the original article on www.globenewswire.com

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.